Open an account

Vericel

VCEL · NASDAQ

$40.58+$0.21 (+0.52%)TodayMarket closed ·
Prev close $40.37

About VCEL

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 398 full-time employees. The company has a differentiated portfolio of cell therapy and specialty biologic products. The company markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The firm also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.

Employees
398
Headquarters
Cambridge, Massachusetts
Listed
Feb 4, 1997
Sector
Health Care
Industry
Biotechnology
Website
vcel.com

VCEL key statistics

Market cap
2.05B
Price-earnings ratio
85.89
Dividend yield
—
Average volume
520.28K
Volume
475.27K
Open price
$40.81
High today
$41.03
Low today
$39.97
52 Week high
$49.32
52 Week low
$28.95

Vericel (VCEL) at a glance

As of Oct 20, 2026, Vericel (VCEL) shares are priced at $40.58, giving the company a market cap of 2.05B and a price-to-earnings ratio of 85.89.

Today the stock has traded between $39.97 and $41.03. The current price is 1.5% above the day's low and 1.1% below its high.

Volume so far is 475.27K shares, in line with the average of 520.28K shares a day.

Over the past year Vericel has ranged from $28.95 to $49.32, and now sits 57% of the way up that range.

Vericel met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported $0.04 per share against an estimate of -$0.0287.

The average analyst price target is $61.78, 52.2% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 3 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 9 analystsAvg $61.78
Low
$55.55
Now
$40.58
High
$75.60

VCEL earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 297.5% on average.

  1. Q3 FY24: reported -$0.02 per share against an estimate of -$0.0495
  2. Q4 FY24: reported $0.38 per share against an estimate of $0.3295
  3. Q1 FY25: reported -$0.23 per share against an estimate of -$0.1288
  4. Q2 FY25: reported -$0.01 per share against an estimate of -$0.0319
  5. Q3 FY25: reported $0.10 per share against an estimate of -$0.0064
  6. Q4 FY25: reported $0.45 per share against an estimate of $0.3978
  7. Q1 FY26: reported -$0.12 per share against an estimate of -$0.1581
  8. Q2 FY26: reported $0.04 per share against an estimate of -$0.0287

VCEL news

  • Press releaseGlobe Newswire

    Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.

  • Press releaseGlobe Newswire

    Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It

  • Press releaseGlobe Newswire

    Regenerative Medicine's Next Chapter: Inside the Race to Make the Body Rebuild Itself

  • Press releaseGlobe Newswire

    The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding It

  • Press releaseGlobe Newswire

    The Newest Name on Nasdaq Wants to Help the Body Rebuild Itself

  • Press releasePRNewswire

    Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines

  • Earnings Scheduled For November 6, 2025

  • Earnings Scheduled For May 8, 2025

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.